Valiant Laboratories Reports Significant Decline in Performance for Q1 2024.
Valiant Laboratories, a microcap pharmaceutical company, has reported a decline in its financial performance for the quarter ending March 2024. The company's net sales, PBT, and PAT have all seen significant decreases compared to the previous four quarters. This has resulted in a 'Strong Sell' rating for the company's stock by MarketsMojo.
Valiant Laboratories, a microcap pharmaceutical company, recently announced its financial results for the quarter ending March 2024. The company's stock has been given a 'Strong Sell' rating by MarketsMOJO.According to the financial report, Valiant Laboratories has seen a significant decline in its performance, with a score of -22 compared to -18 in the previous quarter. This decline can be attributed to various factors, as highlighted by the report.
One of the major factors affecting the company's performance is its net sales, which have fallen by 49.3% to Rs 30.58 crore in the quarter. This is a significant decrease compared to the average net sales of the previous four quarters, which stood at Rs 60.35 crore. The report also mentions that the near-term sales trend for Valiant Laboratories is very negative.
Another key aspect of the financial report is the company's Profit Before Tax less Other Income (PBT), which has fallen by a staggering 829.2% to Rs -5.05 crore in the quarter. This is a significant decline compared to the average PBT of the previous four quarters, which was Rs 0.69 crore. The report also states that the near-term trend for PBT is very negative.
The company's Profit After Tax (PAT) has also seen a decline of 152.0% to Rs -1.22 crore in the quarter, compared to the average PAT of Rs 2.35 crore in the previous four quarters. The report highlights that the near-term trend for PAT is also very negative.
In addition, the report mentions that the net sales for the quarter were the lowest in the last five quarters, standing at Rs 30.58 crore. This further reinforces the negative trend in the company's performance.
Overall, the financial report for Valiant Laboratories for the quarter ending March 2024 shows a significant decline in its performance. The company's stock has been given a 'Strong Sell' rating by MarketsMOJO, indicating a negative outlook for the company.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
